دورية أكاديمية
أعرض في EDS

Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathology.

التفاصيل البيبلوغرافية
العنوان: Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathology.
المؤلفون: Temerozo JR; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Fintelman-Rodrigues N; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Dos Santos MC; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Hottz ED; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Laboratory of Immunothrombosis, Department of Biochemistry, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Minas Gerais, Brazil., Sacramento CQ; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., de Paula Dias da Silva A; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Mandacaru SC; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Laboratory of Toxinology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Dos Santos Moraes EC; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Laboratory of Toxinology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Trugilho MRO; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; Laboratory of Toxinology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Gesto JSM; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Ferreira MA; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Saraiva FB; Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Palhinha L; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Martins-Gonçalves R; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Azevedo-Quintanilha IG; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Abrantes JL; Instituto de Ciências Biomédicas, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil., Righy C; Paulo Niemeyer State Brain Institute (IECPN), Rio de Janeiro, RJ, Brazil.; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Kurtz P; Paulo Niemeyer State Brain Institute (IECPN), Rio de Janeiro, RJ, Brazil.; D'Or Institute for Research and Education, Rio de Janeiro, RJ, Brazil., Jiang H; MGI Tech Co. Ltd, Building No.11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China., Tan H; MGI Tech Co. Ltd, Building No.11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China., Morel C; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Bou-Habib DC; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Bozza FA; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.; D'Or Institute for Research and Education, Rio de Janeiro, RJ, Brazil., Bozza PT; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil., Souza TML; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil. souzatml@gmail.com.; Center for Technological Development in Health (CDTS), National Institute for Science and Technology on Innovation on Disease Of Neglected Poppulations (INCT/IDPN), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil. souzatml@gmail.com.
المصدر: Microbiome [Microbiome] 2022 Apr 22; Vol. 10 (1), pp. 65. Date of Electronic Publication: 2022 Apr 22.
نوع المنشور: Journal Article; Video-Audio Media; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101615147 Publication Model: Electronic Cited Medium: Internet ISSN: 2049-2618 (Electronic) Linking ISSN: 20492618 NLM ISO Abbreviation: Microbiome Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London: BioMed Central, 2013-
مواضيع طبية MeSH: COVID-19* , Endogenous Retroviruses*/genetics, Critical Illness ; Humans ; Inflammation ; Respiratory System ; SARS-CoV-2
مستخلص: Background: Critically ill 2019 coronavirus disease (COVID-19) patients under invasive mechanical ventilation (IMV) are 10 to 40 times more likely to die than the general population. Although progression from mild to severe COVID-19 has been associated with hypoxia, uncontrolled inflammation, and coagulopathy, the mechanisms involved in the progression to severity are poorly understood.
Methods: The virome of tracheal aspirates (TA) from 25 COVID-19 patients under IMV was assessed through unbiased RNA sequencing (RNA-seq), and correlation analyses were conducted using available clinical data. Unbiased sequences from nasopharyngeal swabs (NS) from mild cases and TA from non-COVID patients were included in our study for further comparisons.
Results: We found higher levels and differential expression of human endogenous retrovirus K (HERV-K) genes in TA from critically ill and deceased patients when comparing nasopharyngeal swabs from mild cases to TA from non-COVID patients. In critically ill patients, higher HERV-K levels were associated with early mortality (within 14 days of diagnosis) in the intensive care unit. Increased HERV-K expression in deceased patients was associated with IL-17-related inflammation, monocyte activation, and an increased consumption of clotting/fibrinolysis factors. Moreover, increased HERV-K expression was detected in human primary monocytes from healthy donors after experimental SARS-CoV-2 infection in vitro.
Conclusion: Our data implicate the levels of HERV-K transcripts in the physiopathology of COVID-19 in the respiratory tract of patients under invasive mechanical ventilation. Video abstract.
(© 2022. The Author(s).)
References: Am J Emerg Med. 2020 Sep;38(9):1722-1726. (PMID: 32738466)
Anesth Analg. 2020 Oct;131(4):993-999. (PMID: 32925314)
J Exp Med. 2021 Mar 1;218(3):. (PMID: 33231615)
Bioinformatics. 2012 Apr 15;28(8):1166-7. (PMID: 22368248)
Front Immunol. 2020 Oct 23;11:580250. (PMID: 33178207)
Ann Hematol. 2020 Jul;99(7):1421-1428. (PMID: 32495027)
Clin Cancer Res. 2013 Nov 15;19(22):6112-25. (PMID: 24081977)
Proc Natl Acad Sci U S A. 2021 May 25;118(21):. (PMID: 33958444)
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549. (PMID: 29722887)
J Emerg Dis Virol. 2017 Aug;3(2):. (PMID: 28868516)
Int J Infect Dis. 2021 Feb;103:25-32. (PMID: 33186704)
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502. (PMID: 33389263)
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84. (PMID: 23716685)
Nat Rev Immunol. 2021 May;21(5):319-329. (PMID: 33824483)
J Antimicrob Chemother. 2021 Jun 18;76(7):1874-1885. (PMID: 33880524)
BMC Biochem. 2011 May 05;12:18. (PMID: 21545744)
J Virol. 2017 Nov 14;91(23):. (PMID: 28931682)
Nat Microbiol. 2021 Jan;6(1):73-86. (PMID: 33340034)
Blood. 2008 Feb 1;111(3):1182-92. (PMID: 17975014)
J Infect Dis. 2014 May 1;209(9):1331-42. (PMID: 24065148)
Am J Respir Crit Care Med. 2021 Jan 15;203(2):192-201. (PMID: 33217246)
EBioMedicine. 2021 Apr;66:103341. (PMID: 33867312)
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66. (PMID: 33119402)
Retrovirology. 2020 May 6;17(1):10. (PMID: 32375827)
J Exp Med. 2005 Aug 1;202(3):415-24. (PMID: 16043521)
Am J Hematol. 2020 Jul;95(7):834-847. (PMID: 32282949)
PLoS One. 2014 Jul 02;9(7):e97984. (PMID: 24988390)
Nucleic Acids Res. 2020 Jan 8;48(D1):D328-D334. (PMID: 31724716)
Nature. 2020 May;581(7809):465-469. (PMID: 32235945)
J Exp Med. 2020 Dec 7;217(12):. (PMID: 32926098)
Microb Pathog. 2018 Feb;115:189-193. (PMID: 29274460)
Front Pharmacol. 2020 Oct 09;11:572009. (PMID: 33162887)
J Gen Virol. 2016 Feb;97(2):344-355. (PMID: 26602089)
Arch Virol. 2017 Dec;162(12):3639-3644. (PMID: 28821995)
Front Cell Infect Microbiol. 2021 Feb 25;11:609160. (PMID: 33732659)
Cell Commun Signal. 2019 Aug 14;17(1):94. (PMID: 31412880)
Trends Immunol. 2017 May;38(5):310-322. (PMID: 28254169)
Nat Protoc. 2016 Jan;11(1):102-17. (PMID: 26658470)
Bioinformatics. 2018 Dec 1;34(23):4121-4123. (PMID: 29790939)
Hum Genomics. 2021 Jan 4;15(1):2. (PMID: 33390179)
Front Pediatr. 2020 May 14;8:244. (PMID: 32478020)
Nat Rev Immunol. 2020 Jun;20(6):355-362. (PMID: 32376901)
Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
Bioinformatics. 2019 Mar 1;35(5):871-873. (PMID: 30124794)
Circulation. 2017 Nov 14;136(20):1920-1935. (PMID: 28935667)
Front Microbiol. 2018 Mar 14;9:462. (PMID: 29593697)
Nat Med. 2020 Oct;26(10):1623-1635. (PMID: 32807934)
Nat Rev Rheumatol. 2010 Apr;6(4):232-41. (PMID: 20177398)
Life Sci. 2020 Sep 15;257:118102. (PMID: 32687918)
Retrovirology. 2011 Nov 08;8:90. (PMID: 22067224)
J Infect Dis. 2021 Mar 3;223(5):785-795. (PMID: 33277988)
Front Microbiol. 2020 Jul 17;11:1690. (PMID: 32765477)
Lancet Microbe. 2020 Nov;1(7):e290-e299. (PMID: 33015653)
Cell. 2020 Sep 17;182(6):1419-1440.e23. (PMID: 32810438)
Sci Rep. 2021 Oct 12;11(1):20254. (PMID: 34642411)
PLoS Pathog. 2020 Dec 16;16(12):e1009127. (PMID: 33326472)
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489. (PMID: 33237286)
PLoS One. 2013 Aug 07;8(8):e70399. (PMID: 23950929)
Front Immunol. 2021 Jul 21;12:720109. (PMID: 34367190)
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. (PMID: 32270184)
Curr Probl Cardiol. 2021 Mar;46(3):100742. (PMID: 33243440)
J Infect Dis. 2021 Aug 2;224(3):395-406. (PMID: 33493287)
Cytometry A. 2020 Sep;97(9):887-890. (PMID: 32654350)
EClinicalMedicine. 2021 Aug;38:100993. (PMID: 34222849)
Cell Death Discov. 2021 Mar 1;7(1):43. (PMID: 33649297)
Antimicrob Agents Chemother. 2020 Sep 21;64(10):. (PMID: 32759267)
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. (PMID: 32320677)
Microbiol Spectr. 2021 Oct 31;9(2):e0126021. (PMID: 34612698)
Lancet. 2003 May 24;361(9371):1773-8. (PMID: 12781536)
Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093)
PLoS Pathog. 2017 Jun 26;13(6):e1006451. (PMID: 28651004)
Lancet Microbe. 2020 May;1(1):e14-e23. (PMID: 32835326)
تواريخ الأحداث: Date Created: 20220423 Date Completed: 20220426 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9024070
DOI: 10.1186/s40168-022-01260-9
PMID: 35459226
قاعدة البيانات: MEDLINE
الوصف
تدمد:2049-2618
DOI:10.1186/s40168-022-01260-9